For researchers in the know!
Read editorials detailing cutting edge developments in the field of nanomedicine and see if there are any up and coming conferences you would like to attend. Explore possible careers within the nanomedicine community or put your research on our map and read information about regulatory authorities ensuring right steps are being taken within your research.
Are You New To Nanomedicine?
Information about nanomedicine for people without background knowledge in science is provided. Provides an introduction to nanomedicine, an overview of the nanomedicines currently in clinical use, a glossary of sciencitifc terms often used in nanomedicine and a section on frequently asked questions.
Everything teachers and pupils need to know about Nanomedicine
Fun and simple classroom activities are available for teaching and learning about the key principles of nanotechnology as well as short videos to help with explanations. Up to date nanonews and brief explanations of current research involving nanomedicine are also available.
Welcome to the British Society for Nanomedicine
With the global benefits of the new science of nanomedicine growing each year, the British Society for Nanomedicine has been created to allow open access for industry, academia, clinicians and the public to news and details of ongoing research throughout the UK
Editors-in-Chief Steve Rannard, Raj Bawa, Si-Shen Feng and Andrew Owen
The Journal of Interdisciplinary Nanomedicine (JOIN) is an international peer-reviewed academic journal that aims to provide truly interdisciplinary nanomedicine research. JOIN is now accepting submissions from all relevant fields to be included in the first issue.
The journal contains evidence-based research and translational outputs with high-level contributions from at least two sciences that are peer-reviewed by multiple reviewers tasked to focus primarily on their specialist areas. Multiple first and/or corresponding author status is encouraged so as to provide transparency and acknowledgment for contribution to multidisciplinary work. The Journal embraces submissions from all relevant fields as applied to early stage scientific developments and studies aimed at the progression of nanomedicines towards the clinic, which include engineering, science and medicine, especially materials sciences, life science, clinical science, intellectual property, regulatory issues and policy considerations. JOIN contains original research papers, editorials, review articles, technical notes, and letters to the editor about matters that may benefit the wider readership. Advances that are progressing to application through consolidation of multiple areas of expertise are especially encouraged. Core areas of particular interest include applications of new materials and biological concepts, targeted delivery, molecular biomaterials and nanotechnology in diagnostics, pharmacology, pharmaceutics, toxicology, and clinical outcomes.
For further details please look here
The British Society for Nanomedicine (BSNM) is committed to holding meetings to develop the research community within the UK. This year the BSNM will be hosting a a young researcher's meeting at the University of Liverpool from the 6th to the 7th of August 2015.
This meeting allows postgraduate and postdoctoral researchers from all areas of science undertaking research in the area of Nanomedicine to mix and learn, and in some cases to give their first external oral or poster presentations. We would like to encourage representation from groups conducting Nanomedicine research from across the UK.
There will be two keynote lectures from established scientists in the field as well as presentations from younger members of British Society for Nanomedicine. Posters are also highly encouraged, and these will form the focus of the coffee breaks.
Prices have been kept low to support maximum attendance by young researchers, so please support this event and also join British Society for Nanomedicine.
For further details please look here
by Mike A.W. Eaton, Laurent Levy, Olivier M.A. Fontaine
This is a perspective on the current state of development of nanomedicines in Europe. The view is expressed that a much higher translational success rate could be achieved, with rewards for all stakeholders, if researchers understood the industrial decision points required for new drugs. Getting a drug through the clinic will not help patients unless it is developable by industry. This article is written in the hope that it will help researchers and SMEs to decide where they are in the established process, whether they are making progress and to determine what to do next. It attempts to map the early stages from ideation to first (time) in man (FIM).
Read the full article here